A detailed history of Bank Of America Corp transactions in Merus N.V. stock. As of the latest transaction made, Bank Of America Corp holds 82,646 shares of MRUS stock, worth $4.39 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
82,646
Previous 55,183 49.77%
Holding current value
$4.39 Million
Previous $2.48 Million 96.86%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$39.81 - $60.2 $1.09 Million - $1.65 Million
27,463 Added 49.77%
82,646 $4.89 Million
Q1 2024

May 15, 2024

BUY
$28.03 - $51.82 $1.04 Million - $1.92 Million
37,079 Added 204.81%
55,183 $2.48 Million
Q4 2023

Feb 14, 2024

SELL
$20.06 - $28.66 $88,143 - $125,932
-4,394 Reduced 19.53%
18,104 $497,000
Q2 2023

Aug 14, 2023

SELL
$18.33 - $27.18 $57,684 - $85,535
-3,147 Reduced 12.27%
22,498 $592,000
Q1 2023

May 12, 2023

BUY
$14.25 - $20.5 $2,565 - $3,690
180 Added 0.71%
25,645 $471,000
Q4 2022

Feb 10, 2023

BUY
$12.8 - $23.66 $185,548 - $342,975
14,496 Added 132.15%
25,465 $393,000
Q3 2022

Nov 14, 2022

SELL
$18.64 - $28.93 $80,990 - $125,700
-4,345 Reduced 28.37%
10,969 $220,000
Q2 2022

Aug 12, 2022

SELL
$13.98 - $29.25 $209,336 - $437,989
-14,974 Reduced 49.44%
15,314 $346,000
Q1 2022

May 16, 2022

BUY
$23.58 - $30.91 $180,198 - $236,214
7,642 Added 33.75%
30,288 $801,000
Q4 2021

Feb 08, 2022

BUY
$20.0 - $32.29 $416,300 - $672,116
20,815 Added 1136.81%
22,646 $720,000
Q3 2021

Nov 15, 2021

SELL
$16.48 - $27.23 $8,272 - $13,669
-502 Reduced 21.52%
1,831 $40,000
Q2 2021

Sep 13, 2021

BUY
$20.0 - $25.48 $46,660 - $59,444
2,333 New
2,333 $49,000

Others Institutions Holding MRUS

About Merus N.V.


  • Ticker MRUS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 45,878,200
  • Market Cap $2.44B
  • Description
  • Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase...
More about MRUS
Track This Portfolio

Track Bank Of America Corp Portfolio

Follow Bank Of America Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of America Corp with notifications on news.